FDA approves Madrigal Pharmaceuticals drug as first treatment for common NASH liver disease

FDA approves Madrigal Pharmaceuticals drug as first treatment for common NASH liver disease


In this photo illustration, the Madrigal Pharmaceuticals logo is displayed on a smartphone screen. 

Rafael Henrique | SOPA Images | Lightrocket | Getty Images

The Food and Drug Administration on Thursday approved the first-ever treatment for a common and potentially deadly form of liver disease that affects millions worldwide.

The FDA’s decision means Madrigal Pharmaceuticals has succeeded in a disease area that several larger companies have failed — or are still trying to break into. Madrigal shares jumped more than 20% in extended trading Thursday following the approval.

Novo Nordisk and Eli Lilly are testing their respective blockbuster weight loss injections as treatments for the same kind of liver disease, called nonalcoholic steatohepatitis, or NASH.

Madrigal’s drug, which will be marketed as Rezdiffra, is specifically approved to treat patients with NASH who also have moderate-to-advanced liver scarring. The treatment must be used with diet and exercise, according to the FDA.

NASH is a serious form of liver disease characterized by excess fat buildup and inflammation in the liver and can lead to liver scarring, also known as fibrosis, along with liver failure and liver cancer. The condition is often associated with other health problems, such as high blood pressure, Type 2 diabetes and obesity.

Roughly 6 million to 8 million people in the U.S. have NASH with moderate-to-advanced liver scarring, according to an estimate cited by the FDA.

Madrigal said in a statement that the drug will be available in April. The company also said it has set up an assistance program to help people who don’t have insurance access Rezdiffra. Madrigal has not disclosed how much the treatment will cost.

“Previously, patients with NASH who also have notable liver scarring did not have a medication that could directly address their liver damage,” said Dr. Nikolay Nikolov, acting director of the FDA’s Office of Immunology and Inflammation.

Madrigal’s drug specifically received an “accelerated approval” from the FDA. That designation clears drugs faster if they fill an unmet medical need for serious conditions, and requires the drugmaker to further study the treatment and verify its clinical benefits.

Madrigal’s medication works by activating a thyroid hormone receptor in the liver to help reduce fat accumulation. Patients take it by mouth each day.

In a late-stage study published last month, Rezdiffra helped resolve symptoms of NASH and improve liver scarring without making the condition worse. Notably, the rate of serious adverse events was comparable between the patient group that took the drug and another group that received a placebo.

The most common side effects related to treatment were diarrhea, nausea and vomiting. 

Some specialists have started calling NASH metabolic dysfunction-associated steatohepatitis, or MASH, to avoid potentially stigmatizing language.



Source

Healthy Returns: What to know about a CDC vaccine panel’s votes against a mercury preservative in flu shots
Health

Healthy Returns: What to know about a CDC vaccine panel’s votes against a mercury preservative in flu shots

Biostatistician and epidemiologist Martin Kulldorff, MD, PhD, and Dr. Mina Zadeh, ACIP Executive Secretary, CDC, look on as people present their information to members of the Advisory Committee on Immunization Practices, as the U.S. Centers for Disease Control and Prevention’s (CDC) advisory panel for vaccines convenes, in Atlanta, Georgia, U.S. June 25, 2025. Megan Varner […]

Read More
Medicaid cuts in Trump’s ‘big beautiful’ bill will leave millions uninsured, threaten rural hospitals
Health

Medicaid cuts in Trump’s ‘big beautiful’ bill will leave millions uninsured, threaten rural hospitals

An aerial view of Valley Health Hampshire Memorial Hospital on June 17, 2025 in Romney, W.V. Ricky Carioti | The Washington Post | Getty Images President Donald Trump’s “big, beautiful bill” would make sweeping changes to U.S. health care, leaving millions of vulnerable Americans without health insurance and threatening the hospitals and centers that provide […]

Read More
Moderna’s flu vaccine shows positive late-stage trial results, paving way for combination Covid shot
Health

Moderna’s flu vaccine shows positive late-stage trial results, paving way for combination Covid shot

The Moderna Inc. headquarters in Cambridge, Massachusetts, on March 26, 2024. Adam Glanzman | Bloomberg | Getty Images Moderna on Monday said its experimental mRNA-based flu vaccine produced a stronger immune response than a currently available shot in a late-stage trial, clearing a path forward for the product and the company’s separate combination flu and […]

Read More